Article Text

Download PDFPDF

Cardiovascular mortality in a Western Asian country: results from the Iran Cohort Consortium
  1. Noushin Fahimfar1,
  2. Davood Khalili2,3,
  3. Sadaf Ghajarieh Sepanlou4,
  4. Reza Malekzadeh4,5,
  5. Fereidoun Azizi2,
  6. Mohammad Ali Mansournia1,
  7. Hamidreza Roohafza6,
  8. Mohammad Hassan Emamian7,
  9. Farzad Hadaegh2,
  10. Hossein Poustchi4,
  11. Marjan Mansourian6,8,
  12. Hassan Hashemi9,
  13. Maryam Sharafkhah1,4,
  14. Akram Pourshams4,
  15. Farshad Farzadfar10,
  16. Ewout W Steyerberg11,12,
  17. Akbar Fotouhi1
  1. 1 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2 Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3 Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4 Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  5. 5 Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  6. 6 Isfahan Cardiovascular Research center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  7. 7 Ophthalmic Epidemiology Research Center, Shahroud University of Medical Sciences, Shahroud, Iran
  8. 8 Department of epidemiology and biostatistics, Health school, Isfahan University of Medical Sciences, Isfahan, Iran
  9. 9 Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran
  10. 10 Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  11. 11 Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
  12. 12 Department of Biomedical Data Sciences, LUMC, Leiden, The Netherlands
  1. Correspondence to Professor Reza Malekzadeh; malek{at}ams.ac.ir and Professor Fereidoun Azizi; azizi{at}endocrine.ac.ir

Abstract

Objectives Cardiovascular mortality in Western Asia is high and still rising. However, most data documented on risk prediction has been derived from Western countries and few population-based cohort studies have been conducted in this region. The current study aimed to present the process of pooling data and cardiovascular disease (CVD) mortality incidences for four Iranian cohorts.

Methods From the Iran Cohort Consortium, the Golestan Cohort Study (GCS), Tehran Lipid and Glucose Study, Isfahan Cohort Study (ICS) and the Shahroud Eye Cohort Study (ShECS) were eligible for the current study since they had appropriate data and follow-up visits. Age-standardised CVD mortality rates were estimated for ages 40–80 and 40–65 years. Cox regression was used to compare mortalities among cohorts. Adjusted marginal rates were calculated using Poisson regression.

Results Overall, 61 291 participants (34 880 women) aged 40–80 years, free of CVD at baseline, were included. During 504 606 person-years of follow-up, 1981 CVD deaths (885 women) occurred. Age-standardised/sex-standardised premature CVD mortality rates were estimated from 133 per 100 000 person-years (95% CI 81 to 184) in ShECS to 366 (95% CI 342 to 389) in the GCS. Compared with urban women, rural women had higher CVD mortality in the GCS but not in the ICS. The GCS population had a higher risk of CVD mortality, compared with the others, adjusted for conventional CVD risk factors.

Conclusions The incidence of CVD mortality is high with some differences between urban and rural cohorts in Iran as a Western Asian country. Pooling data facilitates the opportunity to globally evaluate risk prediction models.

  • cardiovascular diseases
  • mortality
  • cohort studies
  • epidemiology of cardiovascular diseases

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors NF designed the study’s analytic strategy, did statistical analysis and wrote the first draft of the manuscript and interpreted the results. DK supervised the work and contributed in the study design, statistical analysis, writing the manuscript and interpreting the results. SGS did some statistical analysis and contributed in writing the manuscript and interpreting the results. RM and FA provided the intellectual input and designs, supervised the data collection, endorsed the protocols to be followed in the study and commented on the draft manuscript. MAM and FF contributed in the study design, provided technical advice for statistical analysis and interpreted the results. HR, MHE, FH, HP, MM, HH, MS and AP contributed in data collection, harmonising the data and preparing the manuscript with critical appraisal. EWS and AF supervised the work, provided technical advice for statistical analysis, interpreted the results and revised the manuscript critically. All authors approved the manuscript to be published.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval This study was approved by the institutional review board of Tehran University of Medical Sciences, Tehran, Iran.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.